RxDoctor Payments Data

Michael Taravella, MD

Cornea and External Diseases Specialist · Aurora, CONPI 1477631737

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 46.7% of the total. Reporting peaked in 2019 at $5,690 and has fallen 96.2% since, to $217 in 2025.

$12,185in general payments, 2019–2025

Across 62 payments — averaging $196.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$6K
  • Harrow Eye, LLC$1K
  • Eyevance Pharmaceuticals LLC$1K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$550
  • Oyster Point Pharma, Inc.$374
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$6,50053%
  • Speaking & faculty fees$6005%
  • Food & beverage$5,08542%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$259,754
Medicare patients
658
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine85$124,760
Cyclosporine32$22,262
Loteprednol Etabonate72$20,065
Prednisolone Acetate503$17,692
Fluorometholone192$16,617
Ketorolac Tromethamine300$12,048
ZirganGanciclovir17$8,131
DurezolDifluprednate13$6,398
TobradexTobramycin/Dexamethasone13$4,469
MoxifloxacinMoxifloxacin Hcl168$4,125
ValacyclovirValacyclovir Hcl46$2,363
Difluprednate12$1,171
Dexamethasone Sodium Phosphate14$845
Brimonidine Tartrate64$752
ErythromycinErythromycin Base61$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$141$20,06572 claims
Bausch & Lomb Americas Inc.Zirgan$550$8,13117 claims
NovartisDurezol$164$6,39813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →